Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28467514 | 0.91 | KMT2A (0.55) | KMT2ACYP2D6NOTUMLTA4HALDH1A1 | |
| SCHEMBL28468740 | 0.91 | KMT2A (0.55) | KMT2ACYP2D6NOTUMLTA4HALDH1A1 | |
| SCHEMBL28467466 | 0.91 | KMT2A (0.55) | KMT2ACYP2D6NOTUMLTA4HALDH1A1 | |
| SCHEMBL28467467 | 0.91 | KMT2A (0.55) | KMT2ACYP2D6NOTUMLTA4HALDH1A1 | |
| SCHEMBL28469518 | 0.91 | KMT2A (0.55) | KMT2ACYP2D6NOTUMLTA4HALDH1A1 | |
| SCHEMBL28467513 | 0.91 | KMT2A (0.55) | KMT2ACYP2D6NOTUMLTA4HALDH1A1 | |
| SCHEMBL28467515 | 0.91 | KMT2A (0.55) | KMT2ACYP2D6NOTUMLTA4HALDH1A1 | |
| SCHEMBL10380722 | 0.91 | KMT2A (0.55) | KMT2ACYP2D6NOTUMLTA4HALDH1A1 | |
| SCHEMBL27481210 | 0.85 | CNR1 (0.57) | KMT2ANOTUMKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5394384 | 0.84 | CNR1 (0.56) | KMT2ANOTUMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2613782-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| WO-2012030685-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030685-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MAPK3, MAPK1, MAP3K1 | KMT2A 2803/4885CYP2D6 1453/4885NOTUM 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.